

PEOPLE

CuraGen (New Haven, CT) has announced the election of **Ronald M. Cresswell** to the company's board of directors. Dr. Cresswell was most recently chief scientific officer and senior vice president of Warner-Lambert Company.

Neurotech (Paris) has announced the appointment of **Bernard Davitian** as executive vice president and chief financial officer. He was most recently CFO at the telecommunications company Fortel, and from 1995 to 2000 he was executive vice president and CFO at Transgene.

Williams S. Ettouati has been named chief business officer at Syrrx (San Diego, CA). Dr. Ettouati was previously vice president of business development at Aurora Biosciences, and served as director, co-CEO, and co-founder of GeneProt.



Paul Friedman

Paul A. Friedman has been named CEO of Incyte Genomics (Palo Alto, CA). Dr. Friedman was formerly president of DuPont Pharmaceuticals Research Laboratories. Incyte also named **Robert Stein**, formerly

DuPont Pharmaceuticals executive vice president of research and preclinical development, as president and chief scientific officer. Current CEO and co-founder **Roy A. Whitfield** has been elected chairman of Incyte's board, succeeding co-founder **Randy Scott**. Dr. Friedman, Dr. Stein, and **Julian Baker**, managing partner of Baker/Tisch Investments, have also been elected to the board.

Cell Therapeutics (Seattle, WA) has named **Vartan Gregorian**, president of the Carnegie Corporation, to its board of directors. Dr. Gregorian served as the 16th president of Brown University from 1988 to 1997, and is currently on the boards of the Institute for Advanced Study at Princeton, Human Rights Watch, McGraw-Hill, and the Museum of Modern Art in New York.

Bristol-Myers Squibb (New York) has announced the appointment of **Tamar D. Howson** as senior vice president, corporate development. Ms. Howson was previously senior vice president and director of business development at SmithKline Beecham, and also managed SR One Ltd., SmithKline's venture capital fund. In conjunction with her appointment, she has resigned her position as a non-executive director for SkyePharma.

IntraBiotics Pharmaceuticals (Mountain View, CA) has announced the resignation of president, CEO, and chairman **Kenneth J. Kelley** to pursue other interests. **Henry J. Fuchs**, currently vice president of clinical affairs, has been promoted to president and the newly created position of chief operating officer.

V. Bryan Lawlis has been appointed to the position of COO at Aradigm (Hayward, CA). Dr. Lawlis was previously acting chairman, president, and CEO of Diosynth RTP, formerly Covance Biotechnology Services. In addition, Aradigm also announced the departure of **Igor Gonda** as chief scientific officer. Dr. Gonda joined Aradigm in 1995 and was elected to the board of directors in 2001. In his new position, he will serve as CEO and managing director of Acrux Ltd. in Melbourne, Australia.

Beyond Genomics (Waltham, MA) has announced the appointment of **Stephen Naylor** as chief technology officer. Dr. Naylor joins the company from the Mayo Clinic, where he was the founding director of the biomedical mass spectrometry and functional proteomics facility, as well as professor of biochemistry and molecular biology, and professor of molecular pharmacology and experimental therapeutics.

Texas Biotechnology Corp. (Houston, TX) has named **William R. Ringo, Jr.** to its board of directors. Mr. Ringo joined Eli Lilly and Co. in 1973 as a sales representative, and has since held key management positions including president and general manager of Eli Lilly Canada, president of internal medicine products, and president of oncology and critical care products.

Astex Technology (Cambridge, UK) has appointed **Jon Saxe** to its board of directors. Mr. Saxe was previously president of Protein Design Labs and currently serves on the boards of Incyte Genomics, Protein Design Labs, First Horizon Pharmaceuticals, and ID Biomedical Corp.

Michael Sherman has joined Immusol (San Diego, CA) as vice president, medical and clinical affairs. Previously, he served as vice president, provider business development and product management for HealthAllies.

Joel S. Smith has been named to the newly created position of executive director for business development at Triad Therapeutics (San Diego, CA). Mr. Smith was most recently executive vice president of strategic development and general counsel of BioQ, a developer of software for the life science industry.